Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — H1 2019 Earnings Presentation
12 slides from Marinomed Biotech's earnings presentation, Aug 30, 2019
Slide 1: Results for half-year 2019 Investor Presentation
Creating innovative therapies for allergy, respiratory and eye diseases Results for half-year 2019 Investor Presentation Vienna, 30 August 2019
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Highlights Half-Year 2019
Highlights Half-Year 2019 Strong half-year allows for accelerated development going forward €22.4m Phase III >40 Top-line results for Financing raised in countries launched Budesolv Feb 1, 2019 IPO +9.4% €15.0m H1/19 vs. H1/18; +20.7% Q2 vs. Q1 Venture Debt committed by EIB On track 99.6% for go-to-
Slide 4: Marinosolv with significant milestones
Marinosolv® with significant milestones Progress as promised with future untapped potential Positive Top-line results Market approval process on track Budesolv achieved non-inferiority, i.e. at least Approval process can be continued as planned the same effect as marketed product (Rhinocort Aqua
Slide 5: Tacrosolv – a powerful immunmodulator
Tacrosolv – a powerful immunmodulator Highly potent API with Marinosolv and smart clinical approach Very promising preclinical data1 Risk reduced clinical strategy Dispersion Allergic Conjunctivitis With successful Phase II in allergic conjunctivitis, likely, Phase II for Dry Phase II Eye can be ski
Slide 6: Carragelose products continue expansion
Carragelose® products continue expansion Multiple additional launches and line extensions planned in the coming years Coldamaris lozenges Coldamaris throatspray Coldamaris akut Coldamaris lozenges Coldamaris throatspray Coldamaris akut Coldamaris pro Coldamaris pro junior Coldamaris plus Regulatory
Slide 7: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) €m H1 2019 H1 2018 1 Revenue €m H1 2019 H1 2018 Revenues 1 1.7 1.5 Sale of goods 1.5 1.4 Other income 0.3 0.5 License revenues 0.0 0.1 Other net gains/losses 0.0 0.0 Other revenues 0.2 0.0 Materials and services expenses 2 (2.7) (1.9) Total revenue 1.7 1.5 Personne
Slide 8: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m H1 2019 YE 2018 1 Therein Austrian Research Premium in the amount of €0.6m (YE 2018: €0.5m) Assets Intangible assets 1.3 1.3 2 Not yet taking into account any disbursement from Property, plant and equipment 0.3 0.2 EIB; total available commitment from
Slide 9: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m H1 2019 YE 2018 1 Therein IPO related paid-in capital of €20.3m (net of transaction costs) and conversion of the Equity and liabilities convertible bond in the amount of €13.1m Share capital 1.5 1.0 Capital reserves 1 40.6 7.0 2 Primar
Slide 10: Statement of cash flows (IFRS)
Statement of cash flows (IFRS) Cash flow characterised by IPO proceeds as well as R&D and IPO spending Reversal Net Cash at of net change in Net D&A Cash at beginning Loss for financial working interest and Investing Financing end of of period the period result capital paid other cash flow cash flow
Slide 11: Positive outlook for 2019
Positive outlook for 2019 Exploiting the potential of our platforms Marinosolv® and Carragelose® Marinosolv® in the focus Targeting a 5 billion dollar market with strong growth perspective Regulatory submission of Budesolv set to take place in 2020 Start of the clinical phase II of Tacrosolv i
Slide 12: www.marinomed.com
: Orrarino www.marinomed.com